K-LOR
FDA Approves Procysbi for Rare Genetic Condition »
"The U.S. Food and Drug Administration today approved Procysbi (cysteamine bitartrate) for the management of nephropathic cystinosis in children and adults. Procysbi was granted orphan product designation because it is intended to treat a rare dis"...
Read the FDA Approves Procysbi for Rare Genetic Condition article »
K-LOR
PATIENT INFORMATION
Physicians should consider reminding the patient of the following:
To dilute each packet of powder in 1/2 glassful of water or other liquid and take each dose after a meal.
To take this medicine following the frequency and amount prescribed by the physician. This is especially important if the patient is also taking diuretics and/or digitalis preparations.
Last reviewed on RxList: 6/28/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional K-LOR Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Women's Health
Find out what women really need.
Updated & New
